Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Securities and Exchange Commission v. Panuwat
Case Number:
4:21-cv-06322
See also:
Court:
Nature of Suit:
Judge:
-
October 19, 2023
SEC Says Jury Should Hear First 'Shadow Trading' Case
The U.S. Securities and Exchange Commission has objected to a former pharmaceutical executive's attempt to shake off the agency's first "shadow trading" lawsuit before the case makes it to a jury, arguing proof exists the defendant knew he was committing insider trading when he purchased a competitor's stock.
-
September 28, 2023
SEC's 'Shadow Trading' Test Case Fails Miserably, Court Told
The former pharmaceutical executive at the center of the U.S. Securities and Exchange Commission's first "shadow trading" case said Thursday that he was the wrong guy to test the novel insider trading theory because the agency has not found any evidence that he acted with ill intent when he traded in a competitor's stock.
-
August 18, 2021
SEC's 'Shadow Trading' Suit Dives Into Murky Area Of Law
The U.S. Securities and Exchange Commission is entering uncharted legal waters with an insider trading suit against a biopharmaceutical executive for allegedly engaging in a practice that's become known as "shadow trading," experts told Law360.
-
August 17, 2021
SEC Sues Exec For Trading On 2016 Pfizer Merger News
The U.S. Securities and Exchange Commission filed an insider trading case Tuesday that claims a former Medivation Inc. executive bought stock options in a rival biopharmaceutical company "within minutes" of learning his own company was being acquired by Pfizer Inc.